inspire


BUSINESS WEST – CONNECTING BUSINESSES INNOVATION News and information on innovation in the South West


Bridging the innovation gap T


he University of Bristol’s EPSRC-funded BristolBridge project is a cross-faculty initiative working on antimicrobial resistance research (AMR). BristolBridge


funds pump-priming projects and builds interdisciplinary collaborations between physical scientists, engineers, mathematicians, biomedical scientists, clinicians and veterinary scientists from across the University and with partners from healthcare and industry, to explore novel and multi-disciplinary ways of tackling the escalating threat of AMR. Such potentially transformative research requires innovation to


translate into clinical practice to benefit patients and human and animal health, and also commercialisation of the research outcomes to generate revenue creating streams to benefit the UK economy. On 3 April, at the University’s School of Chemistry, speakers from


across the innovation and commercialisation landscape met with AMR researchers from various disciplines to discuss the issues and help identify initiatives to progress their research through to commercialisation. The event was jointly organised by Enterprise Europe Network


(EEN) and BristolBridge to identify how open innovation and access to UK and international grants could foster and promote research development and innovation and what steps are necessary to then monetise their ideas. Innovate UK’s family members all contributed significantly to the


event. Speakers from EEN talked about international opportunities for funding and collaboration, IP and developing business models/ value propositions and the entrepreneurship skills necessary for success. The Knowledge Transfer Network and The Medicines Discovery


Catapult Centre discussed the innovation support and resources available to researchers from UK government and forthcoming funding schemes. The University’s Dr Michele Barbour of Pertinax Pharma described her journey in setting up a University spin-out which provided deep insight into how research can be turned into successful innovation and revenue generating activity. Paul O’Collins of EEN emphasised the need to monetise research,


how innovation should be considered as the “commercial exploitation of ideas and research” and encouraged researchers to look at the commercial as well as humanitarian benefits of their work. Colin Cooper, head of business networks at Innovate UK, discussed


the benefit of the event. He said: “Bringing the Innovate UK family together to meet with world class researchers demonstrates the real power of the innovation support in this country and how Innovate UK can drive research and innovation in order to maintain our global position and deliver prosperity to the UK.” Professor Adrian Mulholland, BristolBridge lead, said: “The


importance of translating novel science in to the clinic to help tackle the threat of AMR cannot be overstated. This day has provided an excellent framework for how we may achieve this with external partners to help commercialise our research to benefit all.” Leading on from this event, BristolBridge will host its Annual


Conference to showcase the research it has funded and an Impact & Industry Day centred on building partnerships to tackle the global challenge of AMR on the 10-11 May, 2017. Partners from industry are very welcome to attend and give short


talks on the AMR application areas they are interested in and the opportunities for developing partnerships in AMR research with the University of Bristol.


If you would like to attend, visit www.eventbrite.com/e/ bristolbridge-annual-conference-and-impact-industry-day- tickets-33465488176


18 insight MAY/JUNE 2017


‘Bringing the Innovate UK


family together to meet with world class researchers’


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32